From confusion to clarity: RAS blockade in patients hospitalized with COVID-19

Raymond A Geherty¹, Matthew A Sparks²

Affiliations

¹ Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
² Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Renal Section, Durham Veterans Affairs Health Care System, Durham, North Carolina, USA. Electronic address: matthew.sparks@duke.edu.

PMID: 33753072
PMCID: PMC7973333
DOI: 10.1016/j.kint.2021.02.034

Comment

From confusion to clarity: RAS blockade in patients hospitalized with COVID-19

Raymond A Geherty et al. Kidney Int. 2021 May.

. 2021 May;99(5):1059-1061.

doi: 10.1016/j.kint.2021.02.034. Epub 2021 Mar 19.

Authors

Raymond A Geherty¹, Matthew A Sparks²

Affiliations

¹ Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
² Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Renal Section, Durham Veterans Affairs Health Care System, Durham, North Carolina, USA. Electronic address: matthew.sparks@duke.edu.

PMID: 33753072
PMCID: PMC7973333
DOI: 10.1016/j.kint.2021.02.034

No abstract available

Keywords: ACE inhibitors; ARBs; SARS-CoV-2; hypertension; renin-angiotensin system.

PubMed Disclaimer

Comment on

Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, Rodriguez-Mori JE, Renna N, Chang TI, Corrales-Medina V, Andrade-Villanueva JF, Barbagelata A, Cristodulo-Cortez R, Díaz-Cucho OA, Spaak J, Alfonso CE, Valdivia-Vega R, Villavicencio-Carranza M, Ayala-García RJ, Castro-Callirgos CA, González-Hernández LA, Bernales-Salas EF, Coacalla-Guerra JC, Salinas-Herrera CD, Nicolosi L, Basconcel M, Byrd JB, Sharkoski T, Bendezú-Huasasquiche LE, Chittams J, Edmonston DL, Vasquez CR, Chirinos JA. Cohen JB, et al. Lancet Respir Med. 2021 Mar;9(3):275-284. doi: 10.1016/S2213-2600(20)30558-0. Epub 2021 Jan 7. Lancet Respir Med. 2021. PMID: 33422263 Free PMC article. Clinical Trial.
Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Dos Santos TM, Mazza L, Feldman A, D'Andréa Saba Arruda G, de Albuquerque DC, Camiletti AS, de Sousa AS, de Paula TC, Giusti KGD, Domiciano RAM, Noya-Rabelo MM, Hamilton AM, Loures VA, Dionísio RM, Furquim TAB, De Luca FA, Dos Santos Sousa ÍB, Bandeira BS, Zukowski CN, de Oliveira RGG, Ribeiro NB, de Moraes JL, Petriz JLF, Pimentel AM, Miranda JS, de Jesus Abufaiad BE, Gibson CM, Granger CB, Alexander JH, de Souza OF; BRACE CORONA Investigators. Lopes RD, et al. JAMA. 2021 Jan 19;325(3):254-264. doi: 10.1001/jama.2020.25864. JAMA. 2021. PMID: 33464336 Free PMC article. Clinical Trial.

References

1. Hoffmann M., Kleine-Weber H., Schroeder S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280. - PMC - PubMed
1. Sparks M.A., South A., Welling P. Sound science before quick judgement regarding RAS blockade in COVID-19. Clin J Am Soc Nephrol. 2020;15:714–716. - PMC - PubMed
1. Kreutz R., Algharably E.A.E., Azizi M. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020;116:1688–1699. - PMC - PubMed
1. Kuba K., Imai Y., Rao S. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–879. - PMC - PubMed
1. Cohen J.B., Hanff T.C., William P. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9:275–284. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

From confusion to clarity: RAS blockade in patients hospitalized with COVID-19

Affiliations

From confusion to clarity: RAS blockade in patients hospitalized with COVID-19

Authors

Affiliations

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous